AN2 Therapeutics (ANTX) Assets Average (2022 - 2026)

AN2 Therapeutics (ANTX) has 5 years of Assets Average data on file, last reported at $74.7 million in Q1 2026.

• On a quarterly basis, Assets Average fell 13.83% year-over-year to $74.7 million in Q1 2026; TTM through Mar 2026 was $74.7 million, a 13.83% decrease from a year earlier, with the FY2025 full-year figure at $77.0 million, down 33.27% from the prior year.
• Assets Average for Q1 2026 stood at $74.7 million, up from $64.6 million in the prior quarter.
• Over the last five years, Assets Average for ANTX reached as high as $146.3 million in Q4 2023 and fell as low as $64.6 million in Q4 2025.
• Historically, Assets Average has averaged $101.1 million across 5 years, with a median of $96.8 million in 2023.
• Across the five-year window, Assets Average soared 37.63% in 2023 and plunged 35.13% in 2024, its largest moves.
• Year by year, Assets Average stood at $106.3 million in 2022, then jumped by 37.63% to $146.3 million in 2023, then plunged by 35.13% to $94.9 million in 2024, then sank by 31.93% to $64.6 million in 2025, then increased by 15.68% to $74.7 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $74.7 million in Q1 2026, $64.6 million in Q4 2025, and $71.5 million in Q3 2025.